Unfortunately, recent efforts at pharmacologically targeting AMPK directly using small-molecule pan activators (i.e., those activating all 12 AMPK complexes) have been confounded by significant side-effects such as cardiac hypertrophy, precluding any clinical viability [21]. This evidence concerns the gene PRKAA1 and cardiac hypertrophy.